单核苷酸多态性对消化道恶性肿瘤化疗药物反应和毒性的影响

蔡明志; 梁寒; 潘源

doi:10.3969/j.issn.1000-8179.2012.05.013

单核苷酸多态性对消化道恶性肿瘤化疗药物反应和毒性的影响

doi: 10.3969/j.issn.1000-8179.2012.05.013

天津医科大学附属肿瘤医院胃部肿瘤科, 天津市肿瘤防治重点实验室（天津市300060）

详细信息

通讯作者:
梁寒 tjlianghan@126.com

计量
- 文章访问数: 17
- HTML全文浏览量: 4
- PDF下载量: 1
- 被引次数: 0
出版历程
- 收稿日期: 2011-08-09
- 修回日期: 2011-11-28

Correlation between the Single-nucleotide Polymorphism and the Curative Effect/Side Effect of Chemotherapy for Malignant Gastrointestinal Tumor

Gastric Cancer Surgery Division, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Tianjin Center for Cancer Prevention and Therapy, Tianjin 300060, China

More Information

Corresponding author: Han LIANG, E-mail: tjlianghan@126.com

摘要

摘要: 长期以来绝大多数化疗药物的疗效在不同个体间的差异受到临床医生的高度关注, 其药物反应和毒性不仅与患者的年龄、性别以及药物间相互作用等因素有关, 而且和参与药物代谢的蛋白或酶的表达水平有关。单核苷酸多态性是基因组中最常见的一种遗传变异, 为了揭示个体之间因基因学的差异导致的化疗药物反应以及毒副作用的差异性, 近年来对单核苷酸多态性与化疗药物反应及毒性之间相关性的研究和报道逐渐增多。但对各种单核苷酸多态性能否作为化疗药物反应及毒副作用的预测指标未得出统一定论。本文以消化道恶性肿瘤常用化疗药物为例, 分别对5-氟尿嘧啶(5-FU)类、铂类、紫杉类和伊立替康相关的单核苷酸多态性(SNP)进行综述。
- 单核苷酸多态性(SNP) /
- 胃癌 /
- 大肠癌 /
- 化疗
Abstract: For a long time, clinicians have been paying increasing attention to the differences in the efficacy of anticancer drugs among various patients.The curative effects and possible side effects of chemotherapy are not only related to factors such as age, gender, and drug interactions but also to the expression of the proteins or enzymes involved in the metabolism of chemotherapeutic drugs.Single-nucleotide polymorphism is the most common form of genetic variation.Studies on the correlation between single-nucleotide polymorphism and the effects or side effects of chemotherapy have been increasingly conducted to investigate the differences in the therapeutic effects and side effects of drugs, which are caused by the genetic variations among individuals.However, single-nucleotide polymorphism has not been ascertained as a predictor of the effects and side effects of chemotherapy.The current study reviewed the single-nucleotide polymorphism correlated with fluorouracil, platinum, paclitaxel, and irinotecan, taking chemotherapeutic drugs for malignant gastrointestinal tumor as the example.
- Single-nucleotide polymorphism /
- Gastric cancer /
- Colorectal cancer /
- Chemotherapy

HTML全文

参考文献(42)

[1]	Vignoli M, Nobili S, Napoli C, et al. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil[J]. Pharmacol Res, 2011, 64(3): 242-248. doi: 10.1016/j.phrs.2011.04.006
[2]	Peters GJ, Backus HH, Freemande S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism[J]. Biochim Biophys Acta, 2002, 1587(2-3): 194-205. doi: 10.1016/S0925-4439(02)00082-0
[3]	Chen M, Rahman L, Voeller D, et al. Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas[J]. Oncogene, 2007, 26 (33): 4817-4824. doi: 10.1038/sj.onc.1210273
[4]	Amatori F, Di PA, Del TM, et al. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients[J]. Pharmacogenet Genomics, 2006, 16(11): 809-816. doi: 10.1097/01.fpc.0000230410.07899.bc
[5]	Fernandez-Contreras ME, Sanchez-hemandez JJ, Gonzalez E, et al. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer[J]. Oncol Rep, 2010, 23(5): 1393-1400. http://www.spandidos-publications.com/or/23/5/1393/download
[6]	Tsuji T, Hidaka S, Sawai T, et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer[J]. Clin Cancer Res, 2003, 9(10 Ptl): 3700-3704. http://carcin.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=clincanres&resid=9/10/3700
[7]	Suh KW, Kim JH, Kim YB, et al. Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer[J]. J Gastrointest Surg, 2005, 9(3): 336-342. doi: 10.1016/j.gassur.2004.09.030
[8]	Mandola MV, Stoehlmacher J, Muller-weeks S, et al. A novel sin- gle nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activitylJ]. Cancer Res, 2003, 63(11): 2898-2904.
[9]	Pdez D, Pare L, Altes A, et al. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil[J]. J Cancer Res Clin Oncol, 2010, 136(11): 1681-1689. doi: 10.1007/s00432-010-0826-7
[10]	Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy[J]. Clin Cancer Res, 2004, 10(17): 5880-5888. doi: 10.1158/1078-0432.CCR-04-0169
[11]	Kawakami K, Salonga D, Park JM, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression[J]. Clin Cancer Res, 2001, 7(12): 4096-4101. http://clincancerres.aacrjournals.org/content/7/12/4096.full-text.pdf
[12]	Hur H, KangJ, Kim NK, et al. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer[J]. Int J Rathat Oncol Biol Phys, 2011, 81(3): 669-676. doi: 10.1016/j.ijrobp.2010.06.049
[13]	Pullmann RJ, Abdelmohsen K, Lai A, et al. Differential stability of thymidylate synthase 3'-untranslated region polymorphic variants regulated by AUF1[J]. J Biol Chem, 2006, 281(33): 23456-23463. doi: 10.1074/jbc.M600282200
[14]	Fernandez-contreras ME, Sanchez-hernandez JJ, Gonzalez E, et al. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil -treated colorectal cancer patients[J]. Int J Oncol, 2009, 34(1): 219-229. http://europepmc.org/abstract/MED/19082493
[15]	Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/ oxaliplatin combination chemotherapy in refractory colorectal cancer[J]. BrJ Cancer, 2004, 91(2): 344-354. doi: 10.1038/sj.bjc.6601975
[16]	Jakobsen A, Nielsen JN, Gyldenkerne N, et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity[J]. J Clin Oncol, 2005, 23(7): 1365-1369. doi: 10.1200/JCO.2005.06.219
[17]	Goekkurt E, Al-batran SE, Hartmann JT, et al. Pharmacogeneric analyses of a phase HI trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie[J]. J Clin Oncol, 2009, 27(17): 2863-2873. doi: 10.1200/JCO.2008.19.1718
[18]	Terashima M, Irinoda T, Fujiwara H, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer[J]. Anticancer Res, 2002, 22(2A): 761-768. http://www.ncbi.nlm.nih.gov/pubmed/12014648
[19]	Yanagisawa Y, Maruta F, Iinuma N, et al. Modified Irinotecan/5FU/ Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes[J]. Scan J Gastroenterol, 2007, 42: 477-484. doi: 10.1080/00365520600994418
[20]	Tokunaga Y, Sasaki H, Saito T. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine[J]. Surgery, 2007, 141(3): 346-353. doi: 10.1016/j.surg.2006.06.025
[21]	Morel A, Boisdron-celle M, Fey L, et al. Clinical relevance of differ- ent dihydropyrirnidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance[J]. Mol Cancer Ther, 2006, 5(11): 2895-2904. doi: 10.1158/1535-7163.MCT-06-0327
[22]	Etienne-grimaldi MC, Milano G, Maindrault-goebel F, et al. Methylenetetrahydrofolate reductase(MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients[J]. Br J Clin Pharmacol, 2010, 69(1): 58-66. doi: 10.1111/j.1365-2125.2009.03556.x
[23]	Castillo-Fernandez O, Santibanez M, Bauza A, et al. Methylenetetrahydrofolate reductase polymorphism(677 OT) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic arid[J]. Arch Med Res, 2010, 41(6): 430-435. doi: 10.1016/j.arcmed.2010.08.011
[24]	Afzal S, Jensen SA, Vainer B, et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer[J]. Ann Oncol, 2009, 20(10): 1660-1666. doi: 10.1093/annonc/mdp046
[25]	Liang J, Jiang T, Yao RY, et al. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin -based chemotherapy in metastatic colorectal cancer[J]. Cancer Chemomer Pharmacol, 2010, 66(3): 493-500. doi: 10.1007/s00280-009-1186-3
[26]	Suh KW, Kim JH, Kim Y, et al. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene[J]? Ann Surg Oncol, 2006, 13(11): 1379-1385.
[27]	Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy[J]. J Clin Oncol, 2006, 24(12): 1883-1891. doi: 10.1200/JCO.2005.04.8322
[28]	Chen ZP, Malapetsa A, Monks A, et al. Nucleotide excision repair protein levels vis-a-vis anticancer drug resistance in 60 human tumor cell lines[J]. Ai Zheng, 2002, 21(3): 233-239. http://europepmc.org/abstract/MED/12451985
[29]	Pare L, Marcuello E, Altes A, et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/ 5-fluorouracil as first-line chemotherapy[J]. Br J Cancer, 2008, 99(7): 1050-1055. doi: 10.1038/sj.bjc.6604671
[30]	Li QF, Yao RY, Liu KW, et al. Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer[J]. J Korean Med Sci, 2010, 25 (6): 846-852. doi: 10.3346/jkms.2010.25.6.846
[31]	Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy[J]. J Clin Oncol, 2007, 25(10): 1247-1254. doi: 10.1200/JCO.2006.08.1844
[32]	Park JH, Kim NS, Park JY, et al. MGMT -535G & gt; T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy[J]. J Cancer Res Clin Oncol, 2010, 136(8): 1135-1142. doi: 10.1007/s00432-010-0760-8
[33]	Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer[J]. Anticancer Res, 2001, 21(4B): 3075-3079. http://www.ncbi.nlm.nih.gov/pubmed/?term=A%20polymorphism%20of%20the%20XRCC1%20gene%20predicts%20for%20response%20to%20platinum%20based%20treatment%20in%20advanced%20colorectal%20cancer[J]
[34]	Ott K, Lordick F, Becker K, et al. Glutathione-S-transferase P1, T1 and Ml genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients[J]. Int J Colorectal Dis, 2008, 23(8): 773-782. doi: 10.1007/s00384-008-0490-4
[35]	Lecomte T, Landi B, Beaune P, et al. Glutathione S-transferase P1 polymorphism(Ilel05Val) predicts cumulative neuropathy in pa- tients receiving oxaliplatin-based chemotherapy[J]. Clin Cancer Res, 2006, 12(10): 3050-3056. doi: 10.1158/1078-0432.CCR-05-2076
[36]	Goekkurt E, Hoehn S, Wolschke C, et al. Polymorphisms of glutathione S-transferases(GST) and thymidylate synthase(TS)-novel predictors for response and survival in gastric cancer patients[J]. Br J Cancer, 2006, 94(2): 281-286. doi: 10.1038/sj.bjc.6602891
[37]	Seo BG, Kwon HC, Oh SY, et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in pa tients widr advanced gastric cancer treated with FOLFOX or FOLFIRI[J]. Oncol Rep, 2009, 22(1): 127-136. http://www.ncbi.nlm.nih.gov/pubmed/19513514
[38]	Hamidovic A, Hahn K, Kolesar J. Clinical significance of ABCB1 genotyping in oncology[J]. J Oncol Pharm Pract, 2010, 16(1): 39-44. doi: 10.1177/1078155209104380
[39]	Chang H, Rha SY, Jeung HC, et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy[J]. Oncol Rep, 2010, 23(1): 271-278.
[40]	Saito Y, Sai K, Maekawa K, et al. Close association of UGT1A9 IVS1+ 399C>T with UGT1A128, 6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin(SN-38) glucuronidation in Japanese[J]. Drug Metab Dispos, 2009, 37(2): 272-276. doi: 10.1124/dmd.108.024208
[41]	CoteJF, Kirzin S, Kramar A, et al. UGTIAI polymorphism can predict hematologic toxicity in patients treated with irinotecan[J]. Clin Cancer Res, 2007, 13(11): 3269-3275. doi: 10.1158/1078-0432.CCR-06-2290
[42]	Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma[J]. Cancer, 2008, 112(9): 1932-1940. doi: 10.1002/cncr.23370